TDMS Study 97006-01 Pathology Tables
NTP Experiment-Test: 97006-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 05/11/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:46:56
FINAL#1/RATS
Facility: Battelle Northwest
Chemical CAS #: 108-10-1
Lock Date: 01/24/03
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 97006-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 05/11/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:46:56
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 450 PPM 900 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 14 14 20 15
Natural Death 1 2 4 3
Survivors
Moribund Sacrifice 1
Terminal Sacrifice 35 33 26 32
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (50) (49) (49) (50)
Adenoma 1 (2%)
Liver (50) (50) (50) (50)
Carcinoma, Metastatic, Adrenal Cortex 1 (2%)
Hepatocellular Adenoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Mesentery (18) (17) (15) (15)
Histiocytic Sarcoma 1 (7%)
Schwannoma Malignant 1 (6%)
Oral Mucosa (1)
Squamous Cell Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50)
Carcinoma 1 (2%)
Adrenal Medulla (50) (50) (50) (50)
Pheochromocytoma Malignant 1 (2%) 1 (2%)
Pheochromocytoma Benign 3 (6%) 2 (4%) 2 (4%)
Islets, Pancreatic (50) (50) (50) (50)
Adenoma 1 (2%)
Pituitary Gland (49) (50) (50) (50)
Page 2
NTP Experiment-Test: 97006-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 05/11/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:46:56
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 450 PPM 900 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
Adenoma 24 (49%) 28 (56%) 26 (52%) 30 (60%)
Carcinoma 1 (2%)
Thyroid Gland (50) (50) (50) (50)
Bilateral, C-Cell, Adenoma 1 (2%)
C-Cell, Adenoma 3 (6%) 1 (2%) 2 (4%) 2 (4%)
C-Cell, Carcinoma 1 (2%) 1 (2%) 1 (2%) 2 (4%)
Follicular Cell, Adenoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (50) (50) (50) (50)
Carcinoma 1 (2%) 3 (6%) 1 (2%) 3 (6%)
Ovary (50) (50) (50) (50)
Cystadenocarcinoma 1 (2%)
Cystadenocarcinoma, Metastatic, Ovary 1 (2%)
Granulosa Cell Tumor Benign 1 (2%)
Thecoma Malignant 1 (2%)
Uterus (50) (50) (50) (50)
Carcinoma 1 (2%)
Hemangioma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Leiomyosarcoma 1 (2%)
Polyp Stromal 11 (22%) 4 (8%) 7 (14%) 13 (26%)
Polyp Stromal, Multiple 1 (2%)
Sarcoma Stromal 1 (2%) 1 (2%)
Bilateral, Polyp Stromal 1 (2%) 1 (2%)
Cervix, Polyp Stromal 1 (2%)
Serosa, Hemangioma 1 (2%)
Vagina (2) (1)
Histiocytic Sarcoma 1 (50%)
Sarcoma 1 (50%)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 97006-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 05/11/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:46:56
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 450 PPM 900 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Lymph Node (1) (2) (2) (3)
Deep Cervical, Carcinoma, Metastatic,
Thyroid Gland 1 (50%) 1 (33%)
Lymph Node, Bronchial (9) (12) (8) (7)
Carcinoma, Metastatic, Thyroid Gland 1 (8%) 1 (14%)
Cystadenocarcinoma, Metastatic, Ovary 1 (13%)
Sarcoma, Metastatic, Skin 1 (14%)
Lymph Node, Mandibular (1) (2) (1)
Lymph Node, Mesenteric (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mediastinal (46) (44) (46) (49)
Carcinoma, Metastatic, Zymbal's Gland 1 (2%)
Cystadenocarcinoma, Metastatic, Ovary 1 (2%)
Spleen (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Thymus (47) (49) (49) (49)
Cystadenocarcinoma, Metastatic, Ovary 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (50) (50) (50)
Carcinoma 5 (10%) 8 (16%) 6 (12%) 4 (8%)
Fibroadenoma 17 (34%) 11 (22%) 18 (36%) 10 (20%)
Fibroadenoma, Multiple 5 (10%) 8 (16%) 7 (14%) 8 (16%)
Skin (50) (50) (50) (50)
Basal Cell Carcinoma 1 (2%)
Schwannoma Malignant 1 (2%)
Squamous Cell Papilloma 1 (2%)
Subcutaneous Tissue, Fibroma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Cranium, Carcinoma, Metastatic, Pituitary
Gland 1 (2%)
Skeletal Muscle (10) (5) (8) (14)
Cystadenocarcinoma, Metastatic, Ovary 1 (13%)
Sarcoma 1 (13%)
Page 4
NTP Experiment-Test: 97006-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 05/11/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:46:56
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 450 PPM 900 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM - cont
Schwannoma Malignant 1 (20%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Pineal Gland, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 1 (2%) 1 (2%)
Carcinoma, Metastatic, Clitoral Gland 1 (2%) 1 (2%)
Carcinoma, Metastatic, Thyroid Gland 1 (2%) 1 (2%)
Carcinoma, Metastatic, Zymbal's Gland 1 (2%)
Carcinoma, Metastatic, Adrenal Cortex 1 (2%)
Cystadenocarcinoma, Metastatic, Ovary 1 (2%)
Pheochromocytoma Malignant, Metastatic,
Adrenal Medulla 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Mediastinum, Schwannoma Malignant,
Metastatic, Mesentery 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (50) (50) (50) (50)
Sarcoma 1 (2%)
Zymbal's Gland (3) (1)
Carcinoma 2 (67%) 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Cystadenocarcinoma, Metastatic, Ovary 1 (2%)
Page 5
NTP Experiment-Test: 97006-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 05/11/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:46:56
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 450 PPM 900 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - cont
Mesenchymal Tumor Malignant 2 (4%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Leukemia Mononuclear 14 (28%) 21 (42%) 12 (24%) 16 (32%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 97006-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 05/11/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:46:56
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 450 PPM 900 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 46 46 49 47
Total Primary Neoplasms 91 99 94 103
Total Animals with Benign Neoplasms 44 39 40 40
Total Benign Neoplasms 66 58 67 70
Total Animals with Malignant Neoplasms 22 27 22 25
Total Malignant Neoplasms 25 41 27 33
Total Animals with Metastatic Neoplasms 3 5 4
Total Metastatic Neoplasm 4 12 8
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 97006-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 05/11/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:46:56
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 450 PPM 900 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 14 16 21 29
Natural Death 4 5 4 2
Accidently Killed 1
Survivors
Terminal Sacrifice 32 28 25 19
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Rectum (49) (48) (50) (50)
Adenoma 1 (2%)
Liver (50) (50) (50) (50)
Hepatocellular Adenoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 2 (4%)
Oral Mucosa (2)
Squamous Cell Carcinoma 1 (50%)
Pancreas (50) (48) (50) (50)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (49) (50) (50)
Sarcoma, Metastatic, Lung 1 (2%)
Schwannoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (48) (50) (50)
Histiocytic Sarcoma 1 (2%)
Adrenal Medulla (50) (48) (50) (50)
Pheochromocytoma Malignant 2 (4%) 1 (2%) 2 (4%)
Pheochromocytoma Benign 7 (14%) 4 (8%) 6 (12%) 11 (22%)
Bilateral, Pheochromocytoma Benign 1 (2%) 3 (6%) 4 (8%) 1 (2%)
Islets, Pancreatic (50) (48) (50) (50)
Adenoma 3 (6%) 4 (8%) 1 (2%) 1 (2%)
Carcinoma 4 (8%) 2 (4%) 2 (4%) 1 (2%)
Page 8
NTP Experiment-Test: 97006-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 05/11/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:46:56
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 450 PPM 900 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
Pituitary Gland (50) (49) (50) (50)
Adenoma 35 (70%) 29 (59%) 30 (60%) 29 (58%)
Thyroid Gland (50) (48) (50) (50)
C-Cell, Adenoma 1 (2%) 4 (8%) 4 (8%)
C-Cell, Carcinoma 2 (4%) 3 (6%) 1 (2%)
Follicular Cell, Carcinoma 1 (2%) 2 (4%) 2 (4%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (48) (46) (49) (49)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (49) (50) (50)
Preputial Gland (50) (49) (50) (50)
Carcinoma 1 (2%) 1 (2%)
Testes (50) (50) (50) (50)
Bilateral, Interstitial Cell, Adenoma 28 (56%) 34 (68%) 37 (74%) 38 (76%)
Interstitial Cell, Adenoma 14 (28%) 8 (16%) 7 (14%) 10 (20%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (49) (50) (50)
Histiocytic Sarcoma 1 (2%)
Lymph Node (7) (7) (12) (15)
Deep Cervical, Carcinoma, Metastatic,
Thyroid Gland 1 (14%) 1 (7%)
Lymph Node, Bronchial (11) (13) (12) (7)
Carcinoma, Metastatic, Thyroid Gland 1 (8%)
Sarcoma, Metastatic, Lung 1 (8%)
Lymph Node, Mandibular (1) (1) (3) (2)
Lymph Node, Mesenteric (50) (48) (50) (50)
Lymph Node, Mediastinal (41) (44) (46) (44)
Carcinoma, Metastatic, Thyroid Gland 1 (2%)
Sarcoma, Metastatic, Lung 1 (2%)
Spleen (50) (50) (50) (50)
Hemangioma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Schwannoma Malignant, Metastatic, Heart 1 (2%)
Thymus (49) (47) (50) (49)
Page 9
NTP Experiment-Test: 97006-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 05/11/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:46:56
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 450 PPM 900 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Carcinoma, Metastatic, Thyroid Gland 1 (2%)
Schwannoma Malignant, Metastatic, Heart 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (49) (49) (50) (50)
Carcinoma 2 (4%) 1 (2%) 1 (2%)
Fibroadenoma 2 (4%) 2 (4%) 2 (4%) 1 (2%)
Skin (50) (49) (50) (50)
Basal Cell Adenoma 1 (2%)
Basal Cell Carcinoma 1 (2%)
Fibrous Histiocytoma 1 (2%)
Keratoacanthoma 1 (2%)
Sarcoma 1 (2%) 1 (2%)
Squamous Cell Papilloma 1 (2%)
Sebaceous Gland, Adenoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Fibroma 4 (8%) 1 (2%) 2 (4%) 2 (4%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (3) (3) (4) (6)
Sarcoma, Metastatic, Lung 1 (33%)
Schwannoma Malignant, Metastatic, Heart 1 (33%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (49) (50) (50)
Glioma Malignant 1 (2%)
Granular Cell Tumor Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (50) (48) (50) (50)
Carcinoma, Metastatic, Thyroid Gland 1 (2%)
Lung (50) (49) (50) (50)
Alveolar/Bronchiolar Carcinoma 2 (4%)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Carcinoma, Metastatic, Thyroid Gland 1 (2%)
Page 10
NTP Experiment-Test: 97006-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 05/11/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:46:56
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 450 PPM 900 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Carcinoma, Metastatic, Zymbal's Gland 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Schwannoma Malignant, Metastatic, Heart 1 (2%)
Mediastinum, Sarcoma 2 (4%)
Mediastinum, Schwannoma Malignant,
Metastatic, Heart 1 (2%)
Pleura (50) (49) (50) (50)
Schwannoma Malignant, Metastatic, Heart 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (49) (45) (46) (48)
Carcinoma, Metastatic, Oral Mucosa 1 (2%)
Zymbal's Gland (1) (2)
Carcinoma 1 (100%) 2 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Renal Tubule, Adenoma 2 (4%) 3 (6%)
Renal Tubule, Carcinoma 1 (2%) 2 (4%)
Urinary Bladder (50) (48) (50) (50)
Leiomyoma 1 (2%)
Transitional Epithelium, Papilloma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 2 (4%)
Leukemia Mononuclear 25 (50%) 26 (52%) 32 (64%) 35 (70%)
Mesothelioma Malignant 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 11
NTP Experiment-Test: 97006-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 05/11/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:46:56
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 450 PPM 900 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 50 48 49 50
Total Primary Neoplasms 139 136 133 154
Total Animals with Benign Neoplasms 50 47 47 49
Total Benign Neoplasms 99 89 94 105
Total Animals with Malignant Neoplasms 31 35 34 41
Total Malignant Neoplasms 40 47 39 49
Total Animals with Metastatic Neoplasms 3 3 1 2
Total Metastatic Neoplasm 8 9 2 2
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------